{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T18:14:06Z","timestamp":1777918446487,"version":"3.51.4"},"reference-count":10,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T00:00:00Z","timestamp":1541376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Tumori"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Treatment paradigms for EGFR-mutated non-small cell lung cancer (NSCLC) have successfully evolved since the introduction of osimertinib. The detection of EGFR T790M mutation in plasma or tumor samples obtained at disease progression to first-\/second-generation EGFR inhibitors is mandatory for osimertinib prescription. Nevertheless, pharmacokinetics properties of osimertinib guarantee its usefulness in central nervous system (CNS) disease even in the case of T790M-negative or unknown status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods:<\/jats:title>\n                    <jats:p>In this brief report, we share the clinical histories of two patients with CNS-preeminent progression under first-\/second-generation EGFR inhibitors in which it was not possible to document the presence of T790M resistance mutation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Patient outcomes diverged dramatically due to the differential availability of off-label osimertinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Waiting for the novel molecule to be approved and licensed in first-line treatment, our report of hope and frustration is intended to stress the opportunity of its administration in the case of CNS failure of first-line EGFR inhibition, even in the absence of T790M proof.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0300891618809826","type":"journal-article","created":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T04:09:07Z","timestamp":1541390947000},"page":"NP29-NP33","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Meeting with triumph and disaster: Osimertinib in T790M-unknown CNS progression in\n                    <i>EGFR<\/i>\n                    -mutated non-small cell lung cancer"],"prefix":"10.1177","volume":"104","author":[{"given":"Francesco","family":"Facchinetti","sequence":"first","affiliation":[{"name":"Medical Oncology Unit, University Hospital of Parma, Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Bozzetti","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, University Hospital of Parma, Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Minari","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, University Hospital of Parma, Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Ceccon","sequence":"additional","affiliation":[{"name":"Radiotherapy Unit, University Hospital of Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Zielli","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, University Hospital of Parma, Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Florindo","sequence":"additional","affiliation":[{"name":"Neurology Unit, University Hospital of Parma, Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girolamo","family":"Crisi","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, University Hospital of Parma, Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Tiseo","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, University Hospital of Parma, Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,11,5]]},"reference":[{"key":"bibr1-0300891618809826","unstructured":"Kipling R. If\u2014. https:\/\/www.poetryfoundation.org\/poems\/46473\/if"},{"key":"bibr2-0300891618809826","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0337"},{"key":"bibr3-0300891618809826","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0399"},{"key":"bibr4-0300891618809826","unstructured":"Annex 1: Summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004124\/WC500202022.pdf (accessed October 22, 2018)."},{"key":"bibr5-0300891618809826","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411817"},{"key":"bibr6-0300891618809826","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6758"},{"key":"bibr7-0300891618809826","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.394"},{"key":"bibr8-0300891618809826","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.10.009"},{"key":"bibr9-0300891618809826","volume":"35","author":"Yang J C-H","year":"2017","journal-title":"J Clin Oncol"},{"key":"bibr10-0300891618809826","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137"}],"container-title":["Tumori Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0300891618809826","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0300891618809826","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0300891618809826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:39:09Z","timestamp":1777660749000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0300891618809826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,5]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1177\/0300891618809826"],"URL":"https:\/\/doi.org\/10.1177\/0300891618809826","relation":{},"ISSN":["0300-8916","2038-2529"],"issn-type":[{"value":"0300-8916","type":"print"},{"value":"2038-2529","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,5]]}}}